Local servicesU.S. scenario · USDIllustrative operating case
Pharmacy startup costs and cash planning
A leased U.S. neighborhood community pharmacy selling prescription medicines and a curated OTC and wellness assortment. The paid pharmacist owner leads a staffed secure dispensary and front shop; the case excludes compounding, specialty infusion, delivery fees and separately billed clinical services.
Capital to open
$1,000,000
$750,000–$1,400,000 by launch scope
Year 3 revenue
$4,239,936
Annual modeled sales
Year 3 EBITDA margin
4.3%
Before interest, tax and depreciation
Operating break-even
Month 9
Same opening ramp; not capital payback
Years 1–3 and the opening calculator ramp use one operating base within whole-dollar rounding. Years 4–5 follow the stated annual assumptions.
This operating case allocates $1,000,000 to opening the business and forecasts $184,388 in Year 3 EBITDA. Payroll includes working-owner labor where applicable. These are planning assumptions; EBITDA is not cash available to the owner.
An editorial comparison of operating conditions, not a probability of success, a customer rating or a promise of returns. Read the evidence beside each assessment.
Weighted total
4.2 / 10
The total combines the five assessments below using the published weights.
New U.S. leased community retail pharmacy with paid pharmacist owner, 0.6 FTE staff pharmacist, two technicians, a clerk and qualified relief. Mature dispensing/front-shop operations; local access and contracts remain unverified. No assumed acquisition customer book or clinical-fee advantage.
Barrier to entry
Higher means easier entry.
15% weight
4.0 / 10
Established licensing paths exist, but professional access, a dedicated secure site, stock and coordinated systems dominate entry.
Evidence and assessment basis
Anchor 4: BLS and the California example support specialist access and a defined pharmacy/PIC pathway; DEA and FDA add registration and supply-chain responsibilities. The selected leased format uses obtainable equipment rather than a custom compounding facility, yet stock and installed premises tie up substantial funds. No ordinary unqualified small launch supports the higher staging anchors. Local permissions and bids remain open.
Sources support the underlying facts. The numerical assessment is an editorial judgment.
Competition
Higher means more favorable competitive conditions.
20% weight
3.0 / 10
Network access, close substitutes and national reimbursement pressure limit a new entrant without a verified local advantage.
Evidence and assessment basis
Anchor 3: FTC documents concentrated intermediary access and vertical integration; NCPA documents declining gross profit despite higher sales. The authored pharmacy has no exclusive catchment, effective network contracts or demonstrated retention advantage. Personal service may help but is not evidence of durable pricing protection. A completed local access survey could change the assessment; national structure alone does not close the market.
Sources support the underlying facts. The numerical assessment is an editorial judgment.
Demand stability
Higher means more stable demand.
25% weight
7.0 / 10
Repeat prescription needs support a year-round baseline, while payer changes and competing access affect whether this store captures it.
Evidence and assessment basis
Anchor 7: pharmacist dispensing duties and NCPA prescription activity support frequent recurring medication demand across a diversified assumed local patient base. This case avoids a single specialty customer or seasonal event. Effective payer access, the startup patient base and drug availability remain unresolved; no stress-period evidence justifies anchors 8 to 10. Forecast growth is not used as proof of stability.
Sources support the underlying facts. The numerical assessment is an editorial judgment.
Margin ceiling
Higher means greater supported operating-profit potential.
20% weight
3.0 / 10
Paid mature operations cover costs with a narrow buffer that a lower retained margin can remove.
Evidence and assessment basis
Anchor 3: the reconciled mature case includes paid owner work, the employed roster, employer burden, qualified relief and recurring overhead. A contribution decline from 18.5% to 14% creates an operating loss at unchanged sales; fewer orders and lower-margin drugs remain material exposure. NCPA supports structural margin pressure rather than the exact selected cost share. EBITDA excludes depreciation, financing and tax, and stock/cash requirements constrain the practical surplus.
Sources support the underlying facts. The numerical assessment is an editorial judgment.
Owner dependency
Higher means less dependence on the owner's continuous involvement.
20% weight
3.0 / 10
Staff provide real dispensing and counter capacity, but the owner remains a daily professional and management resource.
Evidence and assessment basis
Anchor 3: the owner supplies the largest pharmacist block and operating leadership; an employed pharmacist covers part of the week, technicians support dispensing and a clerk handles retail work. The relief allowance covers scheduled absence rather than a funded permanent replacement owner. BLS and the state example support differentiated licensed responsibilities. Higher multishift delegation needs a documented responsible lead and full qualified replacement budget.
Sources support the underlying facts. The numerical assessment is an editorial judgment.
Who pays you, and what for
Review the customer, offer and operating scope behind the numbers before adapting them to your own plan.
Patient and setting
A neighborhood pharmacy dispensing outpatient prescriptions and carrying a focused front-shop range.
Order and workload
A retail order may contain multiple prescription fills. Paid orders drive sales; pharmacist-supervised fills also consume clinical capacity.
Receipt and margin
Expected retained sales after payer reductions are compared with actual goods cost. Submitted charges and bank deposits are different measures.
Working owner
The paid pharmacist owner works alongside the employed team and remains responsible for defined management and professional duties.
Premises
1,800-square-foot leased retail site with secure dispensary and private counseling space
Paid team
Pharmacist owner, 0.6 FTE staff pharmacist, two technicians and one retail clerk, plus paid pharmacist relief
Opening schedule
Six days and 58 public hours per week, subject to a compliant staffed calendar
Sales unit
One completed retail order; multiple prescription fills may belong to the same order
Revenue engine
Retail traffic, buyer conversion, repeat orders and product mix; cash collection is tracked separately
Who are you actually bidding against?
National PBM concentration and industry margin pressure are documented. No local pharmacy-access, network or competitor survey establishes an advantage for this site.
Local market assessment pending. The checklist below identifies research to complete; it is not a measured competitor sample.
Compare the questions across each row. Scroll the table horizontally on a small screen →
Competitor research checklist · no measured local sample
Offer to investigate
Compare like for like
Evidence to collect
Chain and grocery pharmacies
Payer participation, opening hours, refill access and convenience.
Current local locations and confirmed network/service terms.
Other community pharmacies
Patient relationships, stock availability and actual service scope.
Dated local observations and verified customer-access information.
Mail-order and network-preferred dispensing
Allowed patient choices, refill delivery and effective patient cost.
Actual plan rules and pharmacy contracts without assuming unrestricted substitution.
What supports the model, and what strains it
These are operating considerations for the scenario, not measured advantages over local competitors.
Potential strengths to validate
Recurring dispensing relationships. Necessary repeat medication needs can support continuity across the year when patients can access the pharmacy.
Inspectable retail drivers. Visitor conversion, returning orders, item mix and retained basket sales can be reconciled in one customer funnel.
Defined initial service scope. A dispensing and front-shop launch avoids treating every clinical add-on as an automatic source of cash.
Tradeoffs to plan around
Professional coverage is fixed. The opening calendar commits licensed labor before a mature patient base is proven.
High sales can mask thin margins. A costly drug can increase turnover without retaining enough contribution to fund the team.
Stock and receipts have different clocks. Wholesaler payments and inventory investment can precede payer cash receipts.
Does this operating role fit you?
Evaluate the work you will do and the cost of replacing it. Review the owner responsibilities in the operating scope.
A fit to explore if you can…
Licensed pharmacist owner willing to provide paid professional work and lead inventory and claims controls.
Operator who can verify networks, retained reimbursement and supplier terms before increasing stock.
Team prepared to fund safe coverage and a slow opening ramp.
Founder treating gross drug charges or high sales growth as cash profit.
Operator relying on unverified payer access, unpaid labor or hypothetical clinical fees.
Where the $1,000,000 goes
Authored use-of-funds allocation for one leased community pharmacy, not a national average or signed quote. Opening inventory is a balance-sheet asset; purchases become expense when sold, so the stock budget is not added again to operating cost. Reserve is separate from fit-out and stock and must be replaced by a monthly cash plan using actual payer and supplier terms. Excludes property purchase, compounding infrastructure, acquisition goodwill and a delivery fleet.
Secure dispensary fit-out and site work
$115,000
Retail shelving, counters and counseling furniture
$35,000
Dispensing systems, POS and network setup
$45,000
Medication refrigeration, monitoring and security
$20,000
Deposits, licensing support and launch training
$30,000
Opening prescription and front-shop inventory
$200,000
Operating and collection-delay cash reserve
$500,000
Installation and opening contingency
$55,000
TotalScenario range $750,000 – $1,400,000$1,000,000
Where does the money come from?
Price, daily volume and the operating calendar define this capacity scenario. Check the sold-unit definition in the operating scope.
Net realized sales per completed retail order$85.00per sold unit
×
Completed retail orders per day, including repeat pickups160modeled daily volume
Prescription fills and OTC/wellness products form the retail basket. The prescribed drug mix and payer terms affect retained sales and acquisition cost together; optional clinical services are outside this forecast.
Seasonality and the opening ramp
Refill cycles provide recurring activity, while acute illness, holidays, stock availability and insurance changes can alter daily demand. This scenario uses an average schedule and an authored ramp rather than an observed seasonal series.
What does the revenue have to cover?
Year 3 annual amounts from the income statement. The bars use the same revenue scale; EBITDA is the residual after the three operating expense lines.
Year 3 revenue$4,239,936
Drug and retail goods, dispensing supplies and variable transaction expense$3,455,548
Rent, utilities, insurance, software, compliance support and recurring upkeep$120,000
EBITDA$184,388
Working-owner pay belongs in payroll. Interest, income taxes, loan principal, replacement equipment and changes in working capital affect cash available for distributions.
Five-year view · scroll the income statement horizontally to compare every year →
Five-year forecast
Authored constant-2026-dollar retail case. The first year uses the same monthly ramp as the calculator; years two through five hold mature throughput and the paid roster constant. Mature orders average 1.2 prescription fills at $65 net realized sales each plus $7 front-shop sales, giving $85 per order. The cost line is 79.5% goods plus 2% variable supplies/transaction expense; net realization already includes expected payer price reductions and noncollection, avoiding a duplicate deduction. Gross submitted drug charges are not sales. Payroll and overhead total $50,000 monthly. Cash receipt and supplier payment dates, financing, depreciation, tax, major replacement and owner distributions remain separate.
RevenueEBITDA
$2.8m
$4.2m
$4.2m
$4.2m
$4.2m
Year 1
EBITDA $-88.2k
Year 2
EBITDA $184.4k
Year 3
EBITDA $184.4k
Year 4
EBITDA $184.4k
Year 5
EBITDA $184.4k
Pharmacy income statement · annual USD
Income statement
Year 1
Year 2
Year 3
Year 4
Year 5
Revenue
$2,766,558
$4,239,936
$4,239,936
$4,239,936
$4,239,936
Drug and retail goods, dispensing supplies and variable transaction expense
Rent, utilities, insurance, software, compliance support and recurring upkeep
−$120,000
−$120,000
−$120,000
−$120,000
−$120,000
EBITDA
−$88,187
$184,388
$184,388
$184,388
$184,388
EBITDA margin
-3.2%
4.3%
4.3%
4.3%
4.3%
Annual forecast and monthly operating reconciliation
Years 1–3 and the opening calculator ramp use one operating base within whole-dollar rounding. Years 4–5 follow the stated annual assumptions.
Original inputs · annual USD · whole-dollar rounding tolerance $5
Check
Annual forecast
Monthly calculator base
Year 1 revenue
$2,766,558
$2,766,558
Year 1 operating result
−$88,187
−$88,187
Year 2 revenue
$4,239,936
$4,239,936
Year 2 operating result
$184,388
$184,388
Year 3 revenue
$4,239,936
$4,239,936
Year 3 operating result
$184,388
$184,388
Year 3 / full-volume annual revenue
$4,239,936
$4,239,936
Year 3 / full-volume annual operating result
$184,388
$184,388
Year 1 uses months 1–12, Year 2 months 13–24 and Year 3 months 25–36. Full-volume rows use mature monthly sales and operating result × 12. The calculator holds price, days, contribution and fixed costs constant; an annual price, staffing or cost change can explain a separate path. Sliders do not change this comparison. Neither column measures cash flow, owner distributions or payback. Agreement tests arithmetic, not demand or cash funding. Input basis.
Set the three inputs to your own plan. The ramp starts at 35.0% of mature volume and adds 5.5 percentage points a month.
Monthly revenue over the first 24 months. Darker bars clear the operating break-even line.
Operating break-even
Month 9
Revenue at maturity
$353,328 / mo
Break-even revenue
$270,270 / mo
Break-even volume
123 / day
Fixed costs
$50,000 / mo
Year 1 ramp revenue
$2,766,558
Year 1 ramp operating result
−$88,187
Full-volume operating result
$15,366 / mo
Use the volume definition in the operating scope. This sensitivity keeps fixed costs and contribution margin constant; it does not rebuild the annual income statement. Operating break-even covers monthly fixed operating costs. It does not recover the opening investment.
Two numbers that decide the outcome
Price and daily throughput define the operating case. The range endpoints are sensitivity scenarios; test whether your location can support them.
Net realized sales per completed retail order
$70.00$100.00
$85.00
this model
Completed retail orders per day, including repeat pickups
100190
160
this model
What if the schedule is lighter, or fuller?
Only daily volume changes. All three cases keep the invoice at $85.00, the schedule at 6 days per week, fixed costs at $50,000 per month and contribution margin at 18.5%.
Lower throughput
Use the low end to test a thinner schedule.
Completed retail orders per day, including repeat pickups
100
Mature monthly revenue
$220,830
Operating break-even
Not reached
Not reached in the 24-month ramp.
Base throughput
The current modeled daily schedule.
Completed retail orders per day, including repeat pickups
160
Mature monthly revenue
$353,328
Operating break-even
Month 9
First month contribution covers fixed costs.
Higher throughput
Validate the operating capacity first.
Completed retail orders per day, including repeat pickups
190
Mature monthly revenue
$419,577
Operating break-even
Month 7
First month contribution covers fixed costs.
Capital payback needs a cash-flow schedule. The current forecast has no cumulative cash balance after funding, taxes, debt principal and future capital spending. No payback date or lowest cash balance is reported.
What can go wrong, and what should you test?
Use these checks to challenge the operating assumptions before taking on commitments.
Reimbursement fails to cover acquisition cost
More dispensing increases turnover but does not retain enough margin after the actual drug invoice.
Check: Reconcile expected claim realization and actual acquisition cost by material drug/payer groups before expanding volume.
Network access does not materialize
Prospective patients cannot use the intended pharmacy under their plans.
Check: Obtain effective participation and reimbursement terms instead of treating an application as a contract.
Collection lag consumes working cash
Payer receipts arrive after payroll and wholesaler payments.
Check: Rebuild a dated receivables/payables plan and stress a longer delay before setting distributions.
Unsafe or unavailable coverage
Commercial targets overwhelm pharmacist time or qualified absence cover cannot be secured.
Check: Approve the actual staff calendar and workload with the responsible pharmacist; reduce sales targets when coverage binds.
Wrong stock or cold-chain failure
Capital sits in slow stock or temperature excursions compromise medication.
Check: Validate the opening assortment, expiry controls, monitoring, backup and supplier-return terms.
Retail template does not describe the business
Independent clinical fees or complex reimbursement rules are mistaken for basket sales.
Check: Adapt the workbook or commission the necessary claim and cash schedules before using it for a decision.
What would invalidate this scenario?
Choose your own go/no-go thresholds before committing funds. The page does not establish a universal stop-loss rule.
Before an unconditional lease
Pause until ownership, professional access, site requirements, payer access and a funded downside have been resolved.
Before ordering opening stock
Do not buy the proposed assortment without supplier terms, storage readiness, drug-level economics and an actual demand basis.
Before opening
Verify applicable approvals, competent staffed cover, operational safeguards and actual pharmacy readiness.
Before adding services
Do not add independently billed clinical or delivery revenue without legal scope, paid time and a supported collection mechanism.
Before distributions
Reconcile cash receipts, wholesale obligations, tax, debt and replenishment needs with available bank cash.
What needs to be true before you proceed?
Treat this page as a starting case to verify. A favorable spreadsheet result is only useful when its price, capacity and cost assumptions can be supported.
Which patients can actually use this pharmacy under effective payer contracts?
What net receipt remains after payer terms and expected noncollection?
How many fills belong to one pickup order?
Which drug groups create sales without sufficient contribution?
Can the pharmacist and technician calendar safely deliver the workload?
Who supplies qualified cover when the owner is absent?
When must the wholesaler be paid, and when does payer cash arrive?
What happens if claim receipts take twice as long?
I would decide whether to pursue this pharmacy by the contribution retained after buying the drugs and the cash needed before payer receipts arrive. A growing prescription counter can still be a weak business when sales rise faster than the margin available to pay the professional team.
The retail funnel is useful for connecting patient visits, repeat pickups and merchandise to one basket. Its limit matters just as much: claim terms and drug acquisition costs can change the retained value of that basket without changing the customer count.
The case pays the working pharmacist owner, employees and qualified relief before interpreting surplus. Technicians create important support capacity, but their presence does not establish that the pharmacist calendar can safely absorb any sales target.
Opening stock and collection-delay cash perform different jobs. Stock makes dispensing possible; the reserve carries payroll, suppliers and a delayed patient-book ramp. Neither becomes an operating gain when turnover increases.
What could change the view
My main concern is buying stock and committing to a full professional calendar before effective payer access and drug-level margins are known. A small reduction in retained contribution can remove the surplus while the responsibility to dispense safely remains.
Who this format suits
This format suits a working pharmacist who wants to lead a staffed community operation and can maintain disciplined purchasing, claims and cash controls. It needs sustained professional participation rather than an assumption of passive ownership.
Before committing
Before an unconditional lease or major stock order, obtain effective network terms, compare representative claim receipts with actual wholesale costs, and join the pharmacist roster to a monthly collection and supplier-payment schedule. Recheck the cash reserve under a longer receipt delay.
Explore the online workbook illustration
This HTML illustration uses the website's scenario. The editable Excel product is sold separately; this view is not a screenshot or an inventory of its worksheets.
Completed retail orders per day, including repeat pickups
160
per day
Operating schedule
6
days / week
Fixed operating costs
$50,000
per month
Contribution margin
18.5%
input assumption
The published calculator and annual forecast are separate views. The downloadable workbook requires its own separate calculation review.
Revenue
The exact model uses visitor conversion and repeat-customer cohorts to generate orders, units, category mix and sales. The online case condenses those outputs into completed retail orders and net realized basket sales.
This section describes the website scenario. It does not show a screenshot of the purchased workbook.
COGS & OPEX
Separate drug and retail acquisition cost from dispensing supplies, variable transaction expense and fixed operating overhead.
This section describes the website scenario. It does not show a screenshot of the purchased workbook.
Payroll
Budget licensed pharmacist coverage, technician supervision, front-counter support and paid owner work with employer costs and absence cover.
This section describes the website scenario. It does not show a screenshot of the purchased workbook.
Financial statements
The verified product description lists income statement, cash flow and balance sheet linked to a five-year forecast.
This section describes the website scenario. It does not show a screenshot of the purchased workbook.
Scenario Analysis
The product description confirms low, base and high comparisons for revenue and operating margins.
This section describes the website scenario. It does not show a screenshot of the purchased workbook.
Explore the separate editable Business Plan and Financial Model below. The online outlines describe this scenario; purchased files have their own examples.
Get the editable files
Word for the written plan. Excel for the assumptions and calculations. One-time prices in USD. Bundle adds both products to one cart.
Confirm these items for your location and operating scope. This checklist does not assert that a particular license, insurance policy or employment arrangement is sufficient.
Professional and site evidence
Applicable pharmacy/entity and pharmacist permissions
Controlled-substance scope and required registrations
Secure dispensary, counseling privacy and storage findings
Commercial evidence
Local pharmacy and patient-access research
Effective payer-network terms and reimbursement schedules
Visitor, conversion, repeat-pickup and fill-per-order tracking
Operating evidence
Qualified weekly roster including breaks and absence cover
Opening assortment, suppliers and reorder rules
Cold-chain, tracing, expiry and suspect-product procedures
Financial evidence
Coordinated installed premises and system quotes
Paid owner, employee burden and qualified relief budget
Monthly inventory, claims receipts, payables and downside cash plan
Where could this model miss your situation?
Most financial inputs are author-selected assumptions. The source register explains what is supported and what still needs local validation.
National scenario
No specific neighborhood, lease, pharmacy license, payer contract or startup cohort verifies these authored inputs.
Product fit and customization
The matched Word plan includes a broader clinical/delivery example. The Excel product is a retail visitor and order funnel; claim reimbursement and payment timing outside that structure require adaptation or customization. The online scenario is separately authored.
Operating result boundary
EBITDA is a pre-depreciation, pre-interest and pre-tax operating proxy; stock funding, cash timing, major replacements and distributions remain separate.
No clinical or legal determination
This planning analysis does not establish safe dispensing capacity, permitted services or compliant ownership in any particular state.
Extended analysis: editorial basis
Prepared from current cited sources and explicit authored assumptions for the stated U.S. pharmacy operating scope. The site owner reviewed and approved this AI-assisted planning case for publication on October 3, 2026. This review does not establish local fieldwork, clinical or legal approval, a purchased-file formula audit, payment or paid-file delivery.
1,800-square-foot leased retail site with secure dispensary and private counseling space
Paid team
Pharmacist owner, 0.6 FTE staff pharmacist, two technicians and one retail clerk, plus paid pharmacist relief
Opening schedule
Six days and 58 public hours per week, subject to a compliant staffed calendar
Sales unit
One completed retail order; multiple prescription fills may belong to the same order
Revenue engine
Retail traffic, buyer conversion, repeat orders and product mix; cash collection is tracked separately
Prepared October 2, 2026 from current U.S. labor, industry, regulator and original vendor evidence. All site-specific financial inputs are explicit authored assumptions, not measured national averages. Revenue is the net earned retail basket after expected reductions and noncollection; paid owner labor precedes operating surplus. The same monthly ramp supplies all five forecast years using 4.33 weeks per month. The simplified calculator tests one basket and contribution share and cannot adjudicate prescription claims, authorize dispensing, model individual PBM contracts or forecast bank receipts. Local licenses, staffing, contracts, demand and bids require verification.
U.S. Census Bureau · primary · accessed October 2, 2026
The 2022 industry 456110 covers retailing prescription and nonprescription drugs and medicines. It supports the retail-pharmacy classification, not permissions, sales or capital.
U.S. Bureau of Labor Statistics · primary · accessed October 2, 2026
May 2025 U.S. median annual wage is $140,910; pharmacies and drug retailers median is $132,940. Licensing, duties and wages support professional staffing context. Selected compensation, cover and recruiting availability remain assumptions.
U.S. Bureau of Labor Statistics · primary · accessed October 2, 2026
May 2025 U.S. median annual wage is $45,750. Technicians support dispensing under pharmacist supervision. This does not establish lawful staffing ratios, individual competence, local wages or throughput.
National Community Pharmacists Association · industry · accessed October 2, 2026
Released October 19, 2025, covering 2024 operations and July 2025 locations. Reports average 67,601 prescriptions per store, higher sales with declining gross profits, and pressure from high-cost drugs and low or below-cost reimbursement. An established-store sample is not startup demand or a local market survey.
Federal Trade Commission · primary · accessed October 2, 2026
July 9, 2024 staff report describes PBM concentration, vertical integration and pressure on independent pharmacy access and reimbursement. Findings are national structural context, not this pharmacy's negotiated contracts or a local competition survey.
California State Board of Pharmacy · primary · accessed October 2, 2026
Current application documents premises, ownership, proposed services and pharmacist-in-charge requirements. California is a concrete jurisdictional example; the national case requires its own state board and local requirements rather than exporting California rules everywhere.
Drug Enforcement Administration · primary · accessed October 2, 2026
2022 revised manual describes pharmacy registration, state authority and controlled-substance responsibilities. It is operational context, not a current legal opinion or permission for a particular pharmacy.
U.S. Food and Drug Administration · primary · accessed October 2, 2026
FDA describes authorized trading partners, tracing records and suspect-product handling. Applicable current exemptions and implementation dates require separate review; this case does not assume an exemption eliminates core supply-chain duties.
Good Neighbor Pharmacy / Cencora · vendor · accessed October 2, 2026
September 5, 2019 guidance identifies premises, inventory, labor and working capital for the initial receivables lag. Its historical dollar estimates and break-even rule are not used as current national estimates. Current budget components and terms are explicitly authored assumptions.
Current manufacturer specification describes a purpose-built 15-cubic-foot medication refrigerator with alarms and monitoring options. Supports equipment scope only; the budget is an installed equipment allowance, not a quoted product price or certification for every drug.
Centers for Medicare & Medicaid Services · primary · accessed October 2, 2026
Page updated September 30, 2026 identifies NADAC acquisition-cost data and pricing tools. Acquisition-cost benchmarks are not a substitute for this pharmacy's actual purchase invoices, payer terms or received cash.
Live exact product checked October 2, 2026: editable six-section Word community-pharmacy plan. Its example includes dispensing, clinical services, adherence support, wellness products and delivery; those extra fee streams are excluded from the narrower StartFigures case. Advertised file delivery was not tested with a paid transaction.
Live exact product checked October 2, 2026: five-year editable workbook using visitors, conversion, repeat cohorts, order frequency, units per order, category mix and prices. Product description warns that payer/reimbursement mechanics outside that funnel need customization. Page evidence verifies described architecture, not formulas or paid delivery.
The authored leased-site case allocates $1 million, including stock and a substantial cash reserve. The lower and higher scopes are planning alternatives, not quoted national averages. Replace them with a coordinated premises, staffing, stock and payment-timing budget.
Does pharmacy revenue mean the submitted drug bill?
No. This case uses expected net earned retail sales after contractual reductions and noncollection. A submitted charge, claim approval and bank deposit are separate events.
Why are orders different from prescriptions?
A single pickup can contain several prescription fills and front-shop products. The calculator counts completed orders; the supporting prescription count is a workload check rather than additional revenue.
Is the pharmacist owner paid?
Yes. Payroll includes owner compensation, an employed pharmacist, two technicians, a retail clerk, employer costs and paid relief. Operating surplus is calculated after that roster.
Are clinical services and delivery fees included?
No. The forecast excludes separately billed consultations, immunizations, tests, compounding and delivery fees. Additional services need lawful scope, paid time and a separate supported revenue mechanism.
Does a profitable month mean cash is available?
No. Prescription receivables, supplier payment terms, stock purchases, debt, tax and replacement needs change cash independently of operating EBITDA.
Will the paid financial model fit every pharmacy?
The exact product uses a retail visitor, repeat-order and category-mix engine. It needs adaptation or customization when prescription reimbursement, payer timing or independent clinical services drive the business outside that structure.
Related business ideas
Compare the capital requirement and operating scope of another business.
